On November 16, at the 100th American Heart Association (AHA) Scientific Sessions 2024 in Chicago, Illinois, US, results were ...

Treatment with tirzepatide demonstrated a 38% decrease in the risk of heart failure outcomes (composite endpoint) compared with placebo. Detailed results were announced from the phase 3 SUMMIT trial ...

The pharmaceutical companies behind Ozempic, Wegovy and other weight-loss meds push to prevent compounding pharmacies from ...

GLP-1 drugs like Ozempic are injectable medications—but a strange new market has emerged selling oral “compounded” versions ...

The trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.

Tirzepatide, currently marketed by Eli Lilly (NYSE:LLY) as Mounjaro and Zepbound for diabetes and weight loss, respectively, ...

In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking ...

HF specialists agree these drugs will be key tools in fighting the obesity-related HFpEF epidemic. Hurdles and questions ...

CHICAGO -- A long-acting GIP/GLP-1 receptor agonist conferred significant clinical benefit for people with obesity and ...

"Obesity contributes to worsening heart failure, and while tirzepatide causes considerable weight loss, research is lacking ...

As millions patients struggled to fill their prescriptions for the new weight loss drugs, many have turned to compounded copies.

SUMMT has shown for the first time that a drug can reduce major heart failure clinical outcomes in patients with heart ...